Heat Biologics Joins Russell Microcap® Index
June 28 2021 - 7:30AM
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, today announced that it
has been added to the Russell Microcap® Index, following the annual
Russell indexes reconstitution, effective after the US market opens
today, June 28, 2021, according to a final list of additions posted
on June 25, 2021.
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in
Russell's appropriate growth and value style indexes. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings, and style
attributes.
Jeff Wolf, Chief Executive Officer of Heat,
commented, “We are extremely pleased to join the Russell Microcap
Index and believe that our inclusion will increase our visibility
and exposure to investors. Joining this index is a reflection of
the progress we have made this year in our clinical programs,
including both our oncology program and COVID-19 vaccine program,
building a strong balance sheet with over $132 million of cash and
short-term investments as of Q1 2021 and increasing shareholder
value.”
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell's US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider. For more information on the Russell Microcap® Index and
the Russell indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, and a COVID-19
vaccine program in preclinical development. In addition, Heat
Biologics is also developing a pipeline of proprietary
immunomodulatory antibodies and cell-based therapies, including
PTX-35 and HS-130 in Phase 1 clinical trials.
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com.
Forward Looking Statement
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 on our current expectations and projections
about future events. In some cases, forward-looking statements can
be identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions. These statements
are based upon current beliefs, expectation, and assumptions and
include statements such as the inclusion in the Russell
Microcap Index increasing Heat’s visibility and exposure to
investors. These statements are subject to a number of risks
and uncertainties, many of which are difficult to predict,
including the impact of the inclusion in the Russell Microcap
Index, the ability of Heat's therapies to perform as designed, to
demonstrate safety and efficacy, as well as results that are
consistent with prior results, the ability of HS-110, in
combination with a CPI to be utilized in multiple treatment
settings of NSCLC and to improve survival benefit for patients with
non-small cell lung cancer (NSCLC), the ability HS-110 to be
administered in combination with first line regimens that include a
CPI as well as addressing high unmet medical needs for CPI
progressors, Heat's vaccine platform to provide protection against
COVID-19, the ability to enroll patients and complete the clinical
trials on time and achieve desired results and benefits, especially
in light of COVID-19, Heat's ability to obtain regulatory approvals
for commercialization of product candidates or to comply with
ongoing regulatory requirements, regulatory limitations relating to
Heat's ability to promote or commercialize its product candidates
for specific indications, acceptance of its product candidates in
the marketplace and the successful development, marketing or sale
of products, Heat's ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, its ability to continue to maintain its
listing on the Nasdaq Capital Market and its ability to retain its
key scientists or management personnel, and the other factors
described in Heat's most recent annual report on Form 10-K filed
with the SEC, and other subsequent filings with the SEC. The
information in this release is provided only as of the date of this
release, and Heat undertakes no obligation to update any
forward-looking statements contained in this release based on new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024